期刊文献+

吗替麦考酚酯致踝关节疼痛1例

A case of ankle pain caused by mycophenolate mofetil
下载PDF
导出
摘要 1例72岁男性患者,诊断为免疫相关性脑炎。2021年7月14日患者脑炎二次复发后开始服用吗替麦考酚酯(MMF)抗免疫治疗,给药日剂量由1 g逐渐增加至2 g,剂量增加后1周,患者出现不明原因的踝关节疼痛、水肿,对症给予硫酸镁外敷和红外线局部照射后缓解。在维持MMF给药日剂量为2 g的过程中,患者踝关节疼痛、水肿持续存在。调整MMF日剂量为1.5 g,治疗的第6天,关节疼痛、水肿症状逐渐缓解并痊愈,患者在院期间未再发生类似情况。 A 72-year-old male patient was diagnosed with immune-related encephalitis.On July 1.4th,2021,he began to take mycophenolate mofetil(MMF)for anti-immune treatment after the second recurrence of encephalitis.The daily dose of MMF was gradually increased from 1 g to 2 g.One week after the dose increase,he developed unexplained ankle pain and edema,which was relieved after symptomatic treatment including external application of magnesium sulfate,infrared ray radiation.During the course of maintaining treatment of MMF with the daily dose of 2 g,the pain and edema of the ankle joint persisted.On the 6th day after the daily dose of MMF was reduced to 1.5 g,the above symptoms gradually relieved.The patient did not experience similar conditions again during the hospital period.
作者 王红伟 高宗真 郝娟 李冬冬 孙艳 WANG Hong-wei;GAO Zong-zhen;HAO Juan;LI Dong-dong;SUN Yan(Department of Pharmacy,Beijing Huasheng Rehabilitation Hospital,Beijing 100075,China)
出处 《中国药物应用与监测》 CAS 2022年第5期350-352,共3页 Chinese Journal of Drug Application and Monitoring
关键词 关节疼痛 药品不良反应 吗替麦考酚酯 剂量相关性 Arthralgia Adverse drug reaction Mycophenolate mofetil Dose correlation
  • 相关文献

参考文献11

二级参考文献100

  • 1李俊杰,李江,郭庆军,滕大洪,孙晓叶,蔡金贞.霉酚酸酯在儿童肝移植中应用的单中心研究[J].实用器官移植电子杂志,2014,2(5):286-288. 被引量:2
  • 2沈兵,谭建明,刘志宏,龚华,包尔敦,范昱.肾移植受者口服多剂霉酚酸酯的临床药代动力学特点[J].肾脏病与透析肾移植杂志,2004,13(5):431-435. 被引量:10
  • 3焦正,沈杰,仲珑瑾,郁韵秋,钟明康.麦考酚酸肠肝循环药动学模型的建立[J].药学学报,2006,41(3):272-276. 被引量:7
  • 4齐铁莉,杨景云,唐松岩.霉酚酸酯治疗类风湿关节炎的临床研究[J].黑龙江医药科学,2006,29(3):33-34. 被引量:2
  • 5Port FK, Merion RM, Goodrich NP, et al. Recent trends and results for organ donation and transplantation in the United States, 2005[J]. Am J Transplant, 2006, 6(5 Pt 2): 1095-1100.
  • 6Nowak I, Shaw LM. Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity [J]. Ther Drug Monit, 1997, 19(3): 358-360.
  • 7Picard N, Ratanasavanh D, Premaud A, et al. Identification of the UDP-glucuronosyhransferase isoforms involved in mycophenolic acid phase II metabolism [J]. Drug Metab Dispos, 2005, 33(1): 139-146.
  • 8Bowalgaha K, Miners JO. The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes [J]. Br J Clin Pharmacol, 2001, 52(5): 605-609.
  • 9Hood KA, Zarembski DG. Mycophenolate mofetil: a unique immunosuppressive agent [J]. Am J Health Syst Pharm, 1997, 54(3): 285-294.
  • 10Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients [J]. Clin Pharmacokinet, 2007, 46(1): 13-58.

共引文献561

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部